Egyptian International Pharmaceutical Investments (CAI:PHAR) E10: E£6.43 (As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£88.21
GF Value E£59.72
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments E10?

Egyptian International Pharmaceutical Investments CAI:PHAR +0.94% 69 E10 is E£6.43 as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 69/100 and a GF Value™ of E£59.72 (Significantly Overvalued). The stock has 12 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Egyptian International Pharmaceutical Investments's adjusted earnings per share data for the three months ended in Mar. 2026 was E£1.683. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is E£6.43 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Egyptian International Pharmaceutical Investments's average E10 Growth Rate was 13.40% per year. During the past 3 years, the average E10 Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Egyptian International Pharmaceutical Investments was 9.10% per year. The lowest was 9.10% per year. And the median was 9.10% per year.

As of today (2026-07-02), Egyptian International Pharmaceutical Investments's current stock price is E£88.21. Egyptian International Pharmaceutical Investments's E10 for the quarter that ended in Mar. 2026 was E£6.43. Egyptian International Pharmaceutical Investments's Shiller PE Ratio of today is 13.72.

During the past 13 years, the highest Shiller PE Ratio of Egyptian International Pharmaceutical Investments was 14.29. The lowest was 4.67. And the median was 7.51.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Egyptian International Pharmaceutical Investments's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=88.21/6.43
=13.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Egyptian International Pharmaceutical Investments was 14.29. The lowest was 4.67. And the median was 7.51.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Egyptian International Pharmaceutical Investments E10 Related Terms


Egyptian International Pharmaceutical Investments E10 Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments E10 Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.37 4.69 5.11 5.67

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 5.88 6.14 6.22 6.43

CAI:PHAR vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Shiller PE Ratio falls into.


CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egyptian International Pharmaceutical Investments's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.683/330.2130*330.2130
=1.683

Current CPI (Mar. 2026) = 330.2130.

Egyptian International Pharmaceutical Investments Quarterly Data

per share eps CPI Adj_EPS
201603 0.905 238.132 1.255
201606 0.819 241.018 1.122
201609 1.271 241.428 1.738
201612 0.643 241.432 0.879
201703 1.168 243.801 1.582
201706 -1.042 244.955 -1.405
201709 4.087 246.819 5.468
201712 1.131 246.524 1.515
201803 1.427 249.554 1.888
201806 1.585 251.989 2.077
201809 0.804 252.439 1.052
201812 1.623 251.233 2.133
201903 1.693 254.202 2.199
201906 1.396 256.143 1.800
201909 0.961 256.759 1.236
201912 1.158 256.974 1.488
202003 1.467 258.115 1.877
202006 0.576 257.797 0.738
202009 0.609 260.280 0.773
202012 1.166 260.474 1.478
202103 1.113 264.877 1.388
202106 0.719 271.696 0.874
202109 0.682 274.310 0.821
202112 1.273 278.802 1.508
202203 1.345 287.504 1.545
202206 0.852 296.311 0.949
202209 0.732 296.808 0.814
202212 2.064 296.797 2.296
202303 1.374 301.836 1.503
202306 2.221 305.109 2.404
202309 0.708 307.789 0.760
202312 1.712 306.746 1.843
202403 3.916 312.332 4.140
202406 1.004 314.175 1.055
202409 1.154 315.301 1.209
202412 1.300 315.605 1.360
202503 2.142 319.799 2.212
202506 2.998 322.561 3.069
202509 1.910 324.800 1.942
202603 1.683 330.213 1.683

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of E£6.43 mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a E10 of E£6.43 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' E10 too high?
Egyptian International Pharmaceutical Investments' current E10 is E£6.43. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' E10 compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' E10 of E£6.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current E10 is E£6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.72, compared to a current price of E£88.21 — trading 47.7% above its estimated fair value. The current E10 is E£6.43. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current E10 is E£6.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£88.21 is trading 47.7% above its estimated GF Value™ of E£59.72. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • E10: E£6.43
  • GF Value™: E£59.72 vs. price of E£88.21 (47.7% above fair value)
  • GF Score™: 69/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£88.21
Price
E£59.72
GF Value